206 related articles for article (PubMed ID: 32705217)
1. Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
Zhou S; Wang R; Xiao H
Oncol Rep; 2020 Sep; 44(3):927-938. PubMed ID: 32705217
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
[TBL] [Abstract][Full Text] [Related]
4. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.
Mukherjee A; Chiang CY; Daifotis HA; Nieman KM; Fahrmann JF; Lastra RR; Romero IL; Fiehn O; Lengyel E
Cancer Res; 2020 Apr; 80(8):1748-1761. PubMed ID: 32054768
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
6. AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.
Badmann S; Mayr D; Schmoeckel E; Hester A; Buschmann C; Beyer S; Kolben T; Kraus F; Chelariu-Raicu A; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Sci Rep; 2022 Feb; 12(1):1862. PubMed ID: 35115586
[TBL] [Abstract][Full Text] [Related]
7. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.
Ricciardelli C; Ween MP; Lokman NA; Tan IA; Pyragius CE; Oehler MK
BMC Cancer; 2013 Oct; 13():476. PubMed ID: 24124770
[TBL] [Abstract][Full Text] [Related]
9. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
10. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
11. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
[TBL] [Abstract][Full Text] [Related]
12. HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.
Schardt JS; Noonan-Shueh M; Oubaid JM; Pottash AE; Williams SC; Hussain A; Lapidus RG; Lipkowitz S; Jay SM
AAPS J; 2019 Apr; 21(3):48. PubMed ID: 30949858
[TBL] [Abstract][Full Text] [Related]
13. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
14. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
15. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
16. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
17. Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma.
Yan JQ; Liu M; Ma YL; Le KD; Dong B; Li GH
Exp Biol Med (Maywood); 2022 Jun; 247(11):910-920. PubMed ID: 35285286
[TBL] [Abstract][Full Text] [Related]
18. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
19. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
